Inotiv, Inc.

NasdaqCM:NOTV Voorraadrapport

Marktkapitalisatie: US$9.9m

Inotiv Beheer

Beheer criteriumcontroles 2/4

De CEO Inotiv is Bob Leasure, benoemd in Jan2019, heeft een ambtstermijn van 7.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.94M, bestaande uit 27.5% salaris en 72.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.39% van de aandelen van het bedrijf, ter waarde $ 236.67K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 4.4 jaar.

Belangrijke informatie

Bob Leasure

Algemeen directeur

US$2.9m

Totale compensatie

Percentage CEO-salaris27.46%
Dienstverband CEO7.3yrs
Eigendom CEO2.4%
Management gemiddelde ambtstermijn4.8yrs
Gemiddelde ambtstermijn bestuur4.4yrs

Recente managementupdates

Recent updates

NOTV: Margin Execution And Higher Future P/E Will Support Upside

Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.

NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement

Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.

NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance

Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.

The Global Shortage of Research Primates and Why It May Matter for Inotiv

Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.

The Hidden Scientific Infrastructure Behind Inotiv.

Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.

NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk

Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.

Why March 6 and March 31 Matter

— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.

NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration

Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.

Inotiv's Margin Discipline Will Reshape Its Financial Future

Inotiv does not need perfection. It needs margin discipline.

Inotiv NAMs Test Center

Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.

NOTV: Raised Fair Value Will Rely On AI Collaboration Execution

Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).

NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk

Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.

NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk

Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).

NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk

Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).

NOTV: Future Margins And Legal Settlement Will Support Share Upside

Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump

Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump

May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump

Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?

Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?
User avatar

NHP Facilities And North American Optimization Will Secure Stability

Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.

Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower

Mar 11
Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Dec 06
Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues

Apr 26
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues

Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Analyse CEO-vergoeding

Hoe is Bob Leasure's beloning veranderd ten opzichte van Inotiv's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2025n/an/a

-US$69m

Sep 30 2025US$3mUS$808k

-US$69m

Jun 30 2025n/an/a

-US$79m

Mar 31 2025n/an/a

-US$87m

Dec 31 2024n/an/a

-US$121m

Sep 30 2024US$2mUS$800k

-US$108m

Jun 30 2024n/an/a

-US$99m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023n/an/a

-US$33m

Sep 30 2023US$5mUS$787k

-US$105m

Jun 30 2023n/an/a

-US$340m

Mar 31 2023n/an/a

-US$345m

Dec 31 2022n/an/a

-US$341m

Sep 30 2022US$11mUS$677k

-US$337m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$77m

Dec 31 2021n/an/a

-US$72m

Sep 30 2021US$1mUS$451k

US$11m

Jun 30 2021n/an/a

-US$279k

Mar 31 2021n/an/a

-US$4m

Dec 31 2020n/an/a

-US$4m

Sep 30 2020US$770kUS$344k

-US$5m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019n/an/a

-US$2m

Sep 30 2019US$474kUS$191k

-US$790k

Compensatie versus markt: De totale vergoeding ($USD 2.94M ) Bob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 621.84K ).

Compensatie versus inkomsten: De vergoeding van Bob is gestegen terwijl het bedrijf verliesgevend is.

CEO

Bob Leasure (65 yo)

7.3yrs
Tenure
US$2,941,549
Compensatie

Mr. Robert W. Leasure, Jr., also known as Bob, has been President, Chief Executive Officer and Director at Inotiv, Inc. (formerly known as Bioanalytical Systems, Inc.) since joining on January 12, 2019. Fr...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Robert Leasure
President7.3yrsUS$2.94m2.39%
$ 236.7k
Beth Taylor
EVP & CFO6.1yrsUS$550.27k0.23%
$ 22.3k
Andrea Castetter
EVP of General Counsel & Corporate Secretary and Chief Compliance Officer2.5yrsUS$543.80k0.055%
$ 5.5k
John Sagartz
Chief Strategy Officer & Director7.8yrsUS$511.26k1.98%
$ 195.8k
Adrian Hardy
Chief Commercial Officer1.8yrsUS$473.54k1.1%
$ 109.1k
Brennan Freeman
VP of Finance4.8yrsgeen gegevensgeen gegevens
John Beattie
Chief Operating Officer of DSAno datageen gegevens0.41%
$ 40.8k
Lizanne Muller
Group President of RMS3.8yrsgeen gegevensgeen gegevens
4.8yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van NOTV wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Robert Leasure
President7.3yrsUS$2.94m2.39%
$ 236.7k
John Sagartz
Chief Strategy Officer & Director7.8yrsUS$511.26k1.98%
$ 195.8k
R. Neff
Independent Chairman8.7yrsUS$238.75k0.35%
$ 35.1k
Nigel Brown
Independent Director4.4yrsUS$187.50k0.19%
$ 18.9k
David Landman
Independent Director3.3yrsUS$185.00k0.51%
$ 51.0k
Michael Harrington
Independent Director2.1yrsUS$188.75k0.11%
$ 10.8k
Mary Coelho
Independent Director2.5yrsUS$197.50k0.10%
$ 10.1k
4.4yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NOTV wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/04/29 08:37
Aandelenkoers aan het einde van de dag2026/04/29 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/09/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Inotiv, Inc. wordt gevolgd door 5 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Matthew HewittCraig-Hallum Capital Group LLC
David WindleyJefferies LLC
Jeffrey CohenLadenburg Thalmann & Company